This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
by Zacks Equity Research
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
AGENPositive Net Change AMRNPositive Net Change PBYIPositive Net Change ANABPositive Net Change
biotechs earnings
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
BEAMPositive Net Change AMRNPositive Net Change LQDAPositive Net Change INDVPositive Net Change
biotechs
GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
by Zacks Equity Research
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
GSKPositive Net Change GILDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
by Zacks Equity Research
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
AMRNPositive Net Change IOVAPositive Net Change INDVPositive Net Change
biotechs cell-therapy earnings medical
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
by Zacks Equity Research
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
RHHBYPositive Net Change BMYPositive Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
by Zacks Equity Research
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
AMRNPositive Net Change INSMPositive Net Change INDVPositive Net Change
biotechs earnings medical pharmaceuticals
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
by Zacks Equity Research
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
AGENPositive Net Change AMRNPositive Net Change LQDAPositive Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
by Zacks Equity Research
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
AGENPositive Net Change AMRNPositive Net Change ADMANegative Net Change LQDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
by Zacks Equity Research
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.
PRGONegative Net Change AMRNPositive Net Change INDVPositive Net Change
biotechs
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
by Zacks Equity Research
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
BMYPositive Net Change SMMTPositive Net Change RVMDPositive Net Change TNGXPositive Net Change
biotechs earnings medical pharmaceuticals